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Highlights
 In England, the access to curative treatment varied by geographical area  Living far from a treatment centre reduces the likelihood of surgical treatment  The most deprived patients with greatest travel time were least likely to have surgery  Increasing curative treatment rates were associated with lower population mortality
Introduction
Lung cancer is one of the three most common cancers in England with 36,637 newly diagnosed cases in 2015 [ONS, 2017] . It is also the commonest cause of death from cancer with 30,520 deaths annually, representing 21% of all cancer deaths [ONS, 2017] . Although survival rates for lung cancer have been improving in England in recent years [1] , they remain poor compared with many other cancers. In addition, survival rates in England are worse than those reported from a number of other countries with equivalent expenditure on healthcare [2, 3] .
Almost 90% of all lung cancers diagnosed in England have non-small cell histology or are diagnosed on clinical grounds without tissue confirmation [4] . Fit, early stage non-small cell lung cancer (NSCLC) patients can be offered potentially curative treatment, either with surgical resection or radiotherapy, often combined with adjuvant chemotherapy. Wide variation in usage of surgical resection for NSCLC patients across England and a clear association between resection rate and survival has previously been demonstrated [5] . Such variation has also been demonstrated in other European countries [6, 7] . This may in part be attributable to patient and disease-related factors with performance status, comorbidity, age (with associated increasing frailty and patient choice) and disease stage all justifiably impacting upon the clinical decision-making process [8] [9] [10] . Differing interpretation of the clinical evidence supporting cancer treatment decisions may, however, result in varying practice [11] and previous smallscale studies have demonstrated wide variation in Multi-Disciplinary Team (MDT) recommendations for identical presentations [12] . As such, variation in quality and access to stage specific treatments may, in part, underpin the relatively poor outcomes seen for NSCLC in the UK [3] . Analyses which focus upon surgery alone will, however, have a limited scope in a population often unfit for such an approach. In this often co-morbid population of NSCLC patients, radical radiotherapy is frequently more appropriate.
Moreover, where surgical resection is not possible, radical radiotherapy can offer potential cure. As such, in order to assess effectiveness of curative treatment for NSCLC at the population level both treatment modalities should be considered. A priori, one could hypothesize that CCGs with high surgical resection rates would have low radical radiotherapy rates and vice versa, due to case-mix factors or historical local treatment preferences favouring one treatment over the other. Alternatively, one could hypothesize that CCGs that had high surgical resection rates also had high radical radiotherapy rates owing to a general appetite for curative treatment.
This study aimed to determine the proportion of NSCLC patients in England undergoing potentially curative treatment and its geographical variation. We aimed to assess the impact of patient and tumour characteristics, and distance to nearest treatment centre on treatment rates and determine the relationship between rates of access to curative treatment and population level survival outcomes. The analyses focussed on adult lung cancer patients only, and excluded 43 patients under the age of 15 and over 100. Finally, we excluded 75 patients with unknown vital status. The final data set thus included 144,357 adult NSCLC patients, of whom 68% had a histological and/or cytological confirmation.
Patient and tumour characteristics
Information on patient demographics and tumour characteristics (including stage, anatomical topography and morphology) were extracted from the core cancer registration data. Information on death was obtained from the Office for National Statistics (ONS).
Socioeconomic deprivation (SED) is based on the income domain of the Indices of Deprivation (version 2015) [13] . Lower Super Output Areas (LSOAs, geographic areas of a consistent size that cover a population of approximately 1,500 persons) were grouped into five SED quintiles, each containing 20% of the population of England. The least deprived quintile was labelled 1 and the most deprived 5.
Patients were assigned to an SED quintile based on their postcode of residence at the time of diagnosis.
Performance status at diagnosis was available through patient level linkage with the National Lung Cancer Audit data [14] .
Comorbidity information was obtained from linked in-patient Hospital Episode Statistics (HES 2015) records [15] . Diagnoses (excluding cancer, for which information was retrieved from cancer registration records) from hospital admissions 27 months to 3 months prior to the lung cancer diagnosis were used to calculate the weighted Charlson comorbidity scores (CCS) [16] . The resulting scores were grouped into four categories of increasing severity (CCS 0, 1, 2, 3+). A small proportion of patients (0.9%) did not have a linked HES record and were assumed to have a CCS of 0.
Treatment
Information on surgical resection was retrieved from linked in-patient and day-case HES records. The cancer registration records were linked to HES records using a matching algorithm based on patient's NHS number, date of birth, sex and postcode at diagnosis. Less than 1% of records did not have a linked inpatient HES record and for these patients we assumed that they did not have any comorbid conditions. Surgical procedures recorded in the HES dataset are coded using the Office of Population, Censuses and Surveys Classification of Surgical Operations and Procedures (4th revision, OPCS-4) [17] . Types of surgical resections were included as previously defined [18] : lobectomy or bilobectomy (68%), partial lobectomy or wedge resection (16%), pneumonectomy (12%), sleeve resection (1%), and other less common procedures (other or unspecified excisions of (or lesions of) trachea, carina, lung, and chest wall, 4%). Surgical procedures from one month before to six months after the date of diagnosis were included. If patients had more than one recorded surgical procedure, the most extensive procedure was used in the analysis.
Information on radiotherapy treatments was retrieved from the linked summary records in the national Radiotherapy Dataset (RTDS). The RTDS contains information on all episodes of radiotherapy delivered, but does not consistently capture the treatment intent, whether it be radical, adjuvant or palliative. In addition, disease coding varies between centres, for example, total attendances are captured in some centres rather than intended fractionation patterns, and radiation dose is not always recorded. We considered all episodes starting within six months from date of diagnosis for which a treatment site code for lung cancer (ICD 10 C33-C34) or unspecified respiratory tract cancer (C78, C80, D38, D02) was recorded in the RTDS. When information on the total radiation dose used was missing, the radiotherapy treatment intent was derived using criteria based on clinical guidelines. Thus, radical treatment was defined as: patients with at least one radiotherapy treatment summary record with either 15 or more attendances (with or without recorded dose); 3, 5 or 8 attendances with a dose higher than 50Gy (stereotactic ablative radiotherapy, SABR); or 3, 5 or 8 attendances without a dose but with stage I or II (reflecting TNM stage I through IIA (N0)) treated at a radiotherapy centre known to have performed SABR during the study period. The identification of SABR treatment was validated within two treating centres. In addition, patients with two radiotherapy episodes delivered to the chest within 2 weeks of each other and which together summed up to more than 15 attendances were classified as having had radical radiotherapy treatment. Lung cancer patients without a linked RTDS record were deemed to have received no radiotherapy treatment. If a patient underwent surgical resection and adjuvant radiotherapy, this was considered as primary surgical treatment in the analyses.
To study geographical variation in treatment activity, we calculated the proportion of patients undergoing potentially curative treatment (surgical resection or radical radiotherapy) in each of the 211 Clinical Commissioning Groups (CCG). Because the two treatment modalities pertain to distinct groups of lung cancer patients, separate treatment intensity quintiles were created for surgical resection and radical radiotherapy, where Q1 is the quintile with the lowest and Q5 is the quintile with the highest treatment intensity. Patients were allocated to one of these quintiles based on their residential postcode at diagnosis linked to a CCG.
Travel time was calculated for all patients from their residential postcode at the time of diagnosis to their nearest treatment centre, using the ArcGIS Spatial Analyst module [19] . Given that thoracic surgical centres and radiotherapy treatment centres are not always co-located, distance to each of these was assessed separately. Because the variation in travel time to nearest surgical treatment centre was greater than that to radiotherapy centre, we categorised them separately as 0-15, 16-25, 26-35, 36-55, >55 minutes for nearest thoracic surgical centre and 0-10, 11-20, 21-30, 31-40, >40 minutes for nearest radiotherapy treatment centre. We assumed that each patient was treated at the nearest facility and used the ArcGIS to calculate the shortest travel distance to it. It is recognised that in some cases this would not be the treating centre, however, identifying the geographical extent of each treating centre's catchment was not possible due to the lack of fixed health administrative boundaries, and thus nearest centre was used. Inaccurate or obsolete residential postcodes gave rise to missing travel times (0.5%).
Data analysis
The distribution of the patient characteristics (age, sex, SED, performance status, comorbidity) and tumour characteristics (stage, topography and morphology) were tabulated among all NSCLC patients and among patients undergoing surgical resection or radical radiotherapy. We used the Mantel-Haenszel test with 1 degree of freedom to assess the differences in case-mix by type of curative treatment, with the exception of age for which a Kruskal-Wallis rank test with 2 degrees of freedom was used.
The proportions of patients undergoing potentially curative treatment, radical radiotherapy and surgical resection by CCG were plotted. To assess the relationship between the two curative treatment modalities at CCG level, a scatterplot depicting the proportion of NSCLC patients undergoing either radical radiotherapy or surgical resection by CCG was created.
We used univariable and multivariable logistic regression to assess the association of distance to nearest treatment centre, patient and tumour characteristics with surgical resection and radical radiotherapy. We computed χ² values and p-values for trend and heterogeneity, where appropriate. To assess the combined effect of travel time and socioeconomic deprivation on the likelihood of receiving treatment the odds ratios for undergoing surgical resection or receiving radical radiotherapy were calculated relative to the least deprived quintile group living closest to a thoracic centre or a radiotherapy centre, respectively.
Cox proportional hazards regression analyses were used to assess the association between CCG treatment intensity quintiles of surgical resection and radical radiotherapy and survival. For patients not undergoing curative treatment survival time was calculated from the date of diagnosis to death or censoring date. In order to avoid immortal time bias, for patients undergoing treatment survival time was calculated from the date of surgery or the starting date of radical radiotherapy. All patients were followed up until the date of death or censored on 31/12/2016. Multivariable models included CCG treatment intensity (surgical resection or radical radiotherapy) quintile with adjustment for age, sex, SED, performance status, comorbidity and disease stage. In addition to standard Cox regression models, we ran shared-frailty Cox models with CCG as a random effect to account for potential unobserved variation in survival related to living in distinct geographical areas. We found a significant frailty effect for all models considered and therefore the results from the shared-frailty Cox models are reported here. We computed χ² values and p-values for trend and heterogeneity, where appropriate.
To account for missing data, we also performed analyses based on imputed data. We used multiple imputation by chained equations to impute the missing data for stage and performance status. Twenty imputed datasets were created. We imputed the missing values for stage and performance status treatment using a model that included travel time, diagnosis year, age, sex, socio-economic deprivation, comorbidity, morphology, topography and survival time without interaction terms.
All statistical analyses were carried out using Stata version 13.1 (StataCorp, Texas, USA). Table 1 shows the patient and tumour characteristics of 144,357 NSCLC patients. The median age was 73 years (IQR 65-80), and the majority of patients were male (55.4%). Since we included patients from 1
Results
April 2009 to the end of 2013, there were relatively fewer patients diagnosed in 2009 included in this study compared to the other years (15.2% in 2009, compared to 20.6, 21.1, 21.7, and 21.3% of patients diagnosed in 2010-2013). There was a clear gradient of NSCLC patients predominantly living in areas with higher socioeconomic deprivation (26.0% in the most deprived versus 14.0% in the least deprived socioeconomic deprivation quintile). Performance status was unknown for 31.7% of patients, 33.5% of patients did not have a stage recorded, 26.7% had an unspecified topography and 32.0% did not have a histological confirmation.
Of all NSCLC patients, 20.6% underwent potentially curative treatment: 14.0% underwent surgical resection and 6.6% underwent radical radiotherapy. The proportions of patients undergoing surgical resection increased from 12.2% in 2009 to 15.5% in 2013 and radical radiotherapy from 5.5% to 7.8% during the same period. Both surgical resection and radical radiotherapy offer potential cure to NSCLC patients, but patients undergoing either treatment modality differ. Whereas patients with stage I and II may be candidates for surgical resection, radical radiotherapy or chemoradiotherapy is usually the primary treatment modality for potentially curable stage III NSCLC. Patients who underwent surgical resection were younger (p=0.0001), more often female (p<0.0001), were more likely to live in the least socioeconomically deprived areas (p=0.0005), had better performance status (p<0.0001) and lower Charlson comorbidity scores (p=0.0237) than those who underwent radical radiotherapy.
To assess the effect of travel time to treatment centre and case-mix on the odds of undergoing curative treatment, univariable and multivariable logistic regression analyses were performed ( Table 2 ). There was a stark drop off in the odds of undergoing surgical resection associated with age over 75 (adjusted OR 0.76, 0.39 and 0.12 for ages 75-79, 80-85 and 85+, respectively, p-trend <0.0001). There was a less pronounced but significant trend of reduced odds of undergoing radical radiotherapy with age with the highest age group (85+) being almost half as likely compared to those aged <55 years of age (adjusted OR 0.53, 95% CI 0.47-0.61, p-trend <0.0001). Whereas female NSCLC patients were 16% more likely to undergo surgical resection compared to males, there was no association between sex and the odds of undergoing radical radiotherapy. Whereas there was no clear association between diagnosis year and surgical resection in the multivariable model, patients diagnosed more recently were more likely to undergo radical radiotherapy compared to 2009 (adjusted OR 1.41, 95% CI 1.29-1.53 for 2013 versus 2009, p-trend <0.0001). Performance status was more strongly associated with the odds of undergoing surgical resection (adjusted OR 0.02, 95% CI 0.01-0.04 for highest vs lowest, p-trend <0.0001) than radical radiotherapy (adjusted OR 0.04, 95% CI 0.02-0.06 for highest vs lowest, p-trend <0.0001). We observed an increased likelihood of undergoing surgical resection among patients with comorbidity scores 1 and 2 compared with patients without any recorded comorbidity, and patients with comorbidity were also more like to receive radical radiotherapy. Following multiple imputation, the odds ratio of undergoing surgery remained significant for the group of patients with comorbidity score 2, but no significant trend across comorbidity groups was detected. An attenuated but significant trend remained for radiotherapy. The association of stage with surgical resection reflects a 35% reduced likelihood of patients with stage II disease undergoing surgical resection compared to patients with stage I disease (95% CI 0.61-0.70).
The variation in travel time to nearest surgical treatment centre was greater than that to radiotherapy centre (travel time to thoracic centre: median=30 min, IQR , travel time to RT centre: median=24 min, IQR [14-35]). Most thoracic surgery units and radiotherapy centres are located in big cities where levels of deprivation tend to be higher. The proportion of patients living in the most deprived areas was highest in the quintile with shortest travel time to a treatment centre (44% for thoracic surgery centres and 37% for radiotherapy centres) and lowest in the furthest quintile (13.8% for thoracic surgery and 17.0% for radiotherapy centres). The odds ratios of undergoing surgical resection decreased with increasing travel time to a thoracic surgery centre (adjusted OR 0.81, 95% CI 0.76-0.87 for travel time >55 min vs ≤15 min) and there was a significant trend in the odds ratios over the five travel time quintiles (p-trend <0.0001). No clear association was observed for radical radiotherapy. Higher levels of socioeconomic deprivation were associated with lower odds of undergoing surgical resection (adjusted OR 0.91, 95% CI 0.85-0.97 for highest vs lowest, p-trend <0.0001), whereas the opposite was observed for radical radiotherapy (adjusted OR 1.16, 95% CI 1.08-1.25 for highest vs lowest, p-trend <0.0001). For receipt of surgical resection, the adverse effect of travel time increased with increasing levels of deprivation, with the highest magnitude of the travel time trend observed for the most deprived group (Table 3a) . Patients living furthest away from the nearest thoracic surgery unit and resident in areas with the two highest levels of deprivation had the lowest odds of receiving surgery (adjusted OR 0.72, 95% CI 0.60-0.88 and OR 0.73, 95% CI 0.59-0.91 for deprivation quintiles 4 and 5 respectively). There was no clear pattern of variation in access to radical radiotherapy in relation to travel time and socioeconomic deprivation (Table 3b ). For patients resident in the most deprived areas the odds of receiving radical radiotherapy were consistently higher although with little difference by travel time. Figure 1 shows the significant variation in the use of potentially curative treatment by CCG. The proportion of NSCLC patients receiving curative treatment ranged from 11.8% to 31.7. The proportion undergoing surgical resection ranged from 8.9% to 20.2% (panel a) (England average 13.9%), whereas the proportion receiving radical radiotherapy ranged from 0.4% to 16.4% (panel b) (England average 6.4%). We did not find evidence of either positive or inverse correlation between CCG based rates of surgical resection and rates of radical radiotherapy in the scatterplot (Pearson correlation coefficient ρ=-0.03) (panel c). Given the variation in both treatment modalities, we focussed the subsequent survival analyses on CCG variation in intensity of surgical resection and radical radiotherapy separately.
Results from the univariable and multivariable Cox shared-frailty models are shown in Table 4 .
Compared to patients living in areas with the highest surgical resection rates, higher mortality rates were observed for the lower surgical resection quintiles, and some attenuation was observed when adjusted for case-mix (HR 1.08, 95% CI 1.04-1.12 for lowest vs. highest resection quintile, p-trend 0.0001). A similar magnitude was observed for radical radiotherapy quintile (HR 1.06, 95% CI 1.02-1.10 for lowest vs. highest resection quintile, p-trend 0.0034). Among the treated patients only, the associations were reversed although not statistically significant, and trends not clear.
A sensitivity analysis was performed by repeating logistic and Cox regression analyses with imputed data. With the exception of comorbidity (discussed above) the relationships between the independent variables and treatment, and between treatment intensity and mortality were not materially affected by the imputation performed (supplementary data).
Discussion
This study found wide geographical variation in access to potentially curative treatments of 12 to 32% of NSCLC patients receiving potentially curative treatment by CCG, and that this variation stemmed from variation in both surgical resection and radical radiotherapy rates that did not appear to be correlated.
The variation in access to both treatment modalities affected survival of NSCLC patients in England. The surgical resection rate of 16% during the study period is in line with previously published results from the National Lung Cancer Audit [20] . Between 2004 and 2008 major surgical resection rates of 17.5-24% are reported in European studies [6, 7, 21] . Rates in England do not compare favourably, and despite improvements toward the end of the study period, overall resection rates remain low by international comparison. There is limited information regarding rates of radical radiotherapy internationally.
In agreement with previously reported studies [22, 23] we found that increasing travel time to treating centre is significantly associated with lower rates of surgical treatment for lung cancer, but the association with radical radiotherapy treatment was less clear. Furthermore, we found that travel time to the nearest thoracic surgery unit exacerbated the effects of socioeconomic deprivation, with the patients living furthest away from the nearest thoracic surgery unit and resident in areas with the two highest levels of deprivation having significantly lower likelihood of undergoing surgical resection. Travel time did not appear to alter the effects of socioeconomic deprivation on the likelihood of being treated with radical radiotherapy. Travel times to the nearest thoracic centre were greater than for nearest radiotherapy centre, but even when equivalent travel time intervals were analysed, the difference in association persisted (data not shown). An earlier study showed similar associations of a more pronounced association between travel time to nearest hospital and receipt of surgery than radiotherapy in the north of England [23, 24] .
Both patient and organisational reasons could be responsible for this. From a patient perspective, travel implications for radiotherapy could be expected to have a greater impact because of the need for repeated treatments, as opposed to a single hospitalisation for surgery. Travel time can also be a significant burden on carers, and an in-patient stay for surgery may constitute a bigger burden on carers if the distance is greater. Patient travel for treatment is frequently provided free of charge for those undergoing radiotherapy whilst the same is not true for carers travelling to visit hospital. Our finding provides valuable information to commissioners and clinicians about a need for increased vigilance to the risk of reduced access to treatment in the presence of longer travel times, particularly in the presence of socio-economic deprivation [25] . Patient hotels in treatment centres are already recommended and targeting their increased use to this patient group could be considered [26, 27] .
From a health care organisational perspective, the distance to thoracic centre may be related to a difference in the likelihood of being considered for surgical resection based on the hospital where the patient was first seen. Evidence from the National Lung Cancer Audit has shown that patients with NSCLC first seen in a thoracic surgical centre are more likely to have surgery [28] . Variation in the use of appropriate staging investigations, local availability of complex techniques (such as SABR) and intradisciplinary team working may contribute to the observed difference in access to radical radiotherapy.
These factors have not been accounted for here, and further work is required to investigate whether, and what institutional differences account for this variation in order to identify possible strategies to improve treatment rates and outcomes.
Our findings with regard to access to potentially curative treatment in relation to other patient demographics and tumour characteristics are in line with previous reports with regard to increasing age, male sex, poor performance status and advanced stage all associated with lower odds of receiving potentially curative treatment. We observed an increase in the likelihood of undergoing potentially curative treatment for patients with any comorbidity compared with those with no recorded comorbidity. It is plausible that some patients with comorbid conditions requiring inpatient care were under closer clinical surveillance or had been in contact with the health care system and therefore their lung cancer was discovered at an early stage, making them more likely to receive curative treatment. However, it is of interest, that the associations were much attenuated when we applied multiple imputation to account for the missing data for stage and performance status, raising the possibility that the association may result from residual confounding.
It is of interest that increasing level of socioeconomic deprivation was associated with higher access to radiotherapy, which is in contrast to a reverse association between socioeconomic deprivation and surgical resection. The higher rates of radical radiotherapy in patients living in the more deprived areas may well simply be the inverse of the surgical findings, with more deprived patients more likely to be offered or choose radical radiotherapy over surgery. As noted above SED also further exacerbated the reduction in access to surgery associated with longer travel times.
The differences in access to treatment have a clear effect on the outcomes for lung cancer patients, both for surgical resection and for radical radiotherapy. Some attenuation by case-mix was found. When the survival analyses were restricted to the treated patients only, among the surgically resected patients we see diminishing returns of increasing resection rates, possibly indicating that the high treatment areas include more complicated patients. Among the patients treated with radical radiotherapy no such effect was found, possibly indicating that the rate of radical radiotherapy reported here is well below its optimal level. This study is strengthened by assessing rates of treatment across the whole of England acknowledging both surgical and radiotherapy treatments delivered with a view to cure. It does, however, have a number of limitations. The surgical resections identified from the inpatient HES data using the OPCS-4 codes provide a robust measure of surgical treatment intensity in England. The radiotherapy data as available from the RTDS proved more difficult, as only summarised numbers of attendances were available and not fractions, and only 73% of records had a valid dose recorded. Using our algorithm, taking into account time between summarised episodes of radiotherapy attendances, SABR identified by proxy using stage and centre information, the proportion of patients identified as receiving radical radiotherapy increased from 6% to 7.15%. A validation study comparing patients as identified from the RTDS as having undergone radical radiotherapy against trust records from two radiotherapy centres revealed a 95% concordance. Although this shows that we may have missed a small proportion of patients receiving radical radiotherapy, it is unlikely that this is differential misclassification. As such, we feel that both the geographical variation observed and the impact on survival is real.
Another limitation of this study is that we did not have information on use of chemotherapy, and therefore cannot assess the impact in difference between radical radiotherapy alone versus chemoradiotherapy.
Depending on whether use of chemoradiotherapy varies in the same way that radical radiotherapy does, we may be underestimating the impact this variation has on survival. Furthermore, data on stage, performance status and morphology was frequently missing and varied between the group of patients receiving treatment and those not receiving treatment. To assess the impact of missing data sensitivity analysis was performed by repeating regression analyses following multiple imputation. With the exception of comorbidity (discussed above) the relationships between the independent variables and the treatment likelihood, and between treatment intensity and mortality were not materially affected by the imputation performed.
Finally, CCGs were used as the geographical unit for comparison. These were created following the Health and Social Care Act in 2012, and replaced Primary Care Trusts (PCTs) on 1 April 2013, and as such were not present for the time period covered by the data presented here. We are therefore limited to interpret our findings in terms of geographically based treatment intensity quintiles rather than in terms of commissioning structures. Moreover, potentially curative lung cancer treatments are delivered in This study demonstrates significant geographical variation in the use of potentially curative treatment for NSCLC, and that there is no correlation between surgical resection and radical radiotherapy rates. In addition, we found that increasing both surgical resection and radical radiotherapy rates are associated with lower population mortality among all NSCLC patients. Whilst influenced by case-mix this association persists after adjustment, suggesting it may be driven by other factors not studied here, for example institutional and environmental factors or unmeasured confounding variables at patient level. Exploring these additional factors will play an important part in understanding the observed variation in curative treatment rates for NSCLC patients across the English NHS and delivering improvements in both access and outcomes. 
